ScreenPoint Medical Reports the Acquisition of Biomediq, Bolstering its Breast Cancer Risk Evaluation Capabilities

Shots:

• ScreenPoint has acquired Biomediq, enhancing its breast cancer risk evaluation abilities by adding Breast AI platform, Transpara, that uses Mammographic Texture Risk biomarkers to analyze 2D & 3D mammograms & predict short & long-term risk
• ScreenPoint has launched Transpara 2.1, with advanced features like automated breast density evaluation (BIRADS & volumetric) & temporal comparison. Transpara 2.1, incl. Detection, Temporal
• Comparison & Density options, is CE-marked & FDA-cleared
  A 2023 Radiology study highlighted the efficacy of Transpara’s Detection & Density tools with Biomediq’s texture model, showing improved cancer risk prediction with Transpara-based lesion detection, volumetric density assessment & quantitative texture analysis

Ref: PRNewswire | Image: ScreenPoint Medical

Related News:- Boston Scientific Reports the Acquisition of Silk Road Medical

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com